Increased expression of HLA DR2 in acquired aplastic anemia and its impact on response to immunosuppressive therapy

Journal of the Pakistan Medical Association

Volumn 54, Issue 5, 2004, Pages 251-254

  Usman, M ^a   Adil, S N ^a   Moatter, T ^a   Bilwani, F ^a   Arian, S ^a   Khurshid, M ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HLA DR2 ANTIGEN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE;

ADULT; APLASTIC ANEMIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DIAGNOSTIC VALUE; DRUG RESPONSE; FEMALE; GENE FREQUENCY; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; RETROSPECTIVE STUDY; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HISTOCOMPATIBILITY TESTING; HLA-DR2 ANTIGEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 3142631796     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Young NS. Aplastic anemia. Lancet, 1995;346:228-232.
2. Young NS, Maciejenski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997;336:1365-72.
3. Nimer SD, Ireland P, Meshkinpour A, et al. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 1994;84:923-7.
4. Osman Ihan, Beksac M, Arslan O. HLA DR2: a predictive marker in response to cyclosporine therapy in aplastic anemia. Int J Hematol 1997 66:291-5.
5. Shinji N, Hideyuki T. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 1994;84:4257-61.
6. Camitta BM, Thomas ED, Nathan DG. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979;53:504.
7. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation versus immunosuppression for the treatment of severe aplastic anemia. A report of European Bone Marrow Transplant severe aplastic anemia working party. Br J Haematol 1988;70:177.
8. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood 1995;85:3367-77.
9. Jan K, Akie S. The HLA system: advances in Immunology. Review articles. N Engl J Med 2000;343:782.
10. Maciejewski JP, Follmann D, Nakamura R, et al. increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001;98:3513-19.
11. Ihan O, Beksac M, Koc H. HLA DR frequency in Turkish aplastic anemia patients and the impact of HLA DR2 positivity in response rate in patients receiving immunosuppressive therapy. Blood 1995;86:2055.